PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Roberta MinariFrancesco BonattiGiulia MazzaschiAlessandra DodiFrancesco FacchinettiFrancesco GelsominoGloria CinquegraniAnna SquadrilliPaola BordiSebastiano ButiMelissa BersanelliAlessandro LeonettiAgnese CosenzaLeonarda FerriElena RapacchiFederico QuainiAndrea ArdizzoniMarcello TiseoPublished in: Tumori (2021)
PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.